News

The program, which will be managed by Idis MA, will enable individual adolescents and children as young as 12 months old with high risk neuroblastoma to receive UNITUXIN

The proceeds will fund the further development and advancement of the Company’s product pipeline, including therapeutic antibodies designed to optimize anti-tumor immune responses in synergy with checkpoint inhibitors

IKERVIS is the first and only topical ciclosporin preparation licensed for the treatment of severe keratitis in patients with dry eye disease in the UK. It is estimated

The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes

RPL554 is the company’s lead drug, which is being evaluated in asthma and chronic obstructive pulmonary disease (COPD). The drug is a novel inhaled PDE3/PDE4 inhibitor with anti-inflammatory

Novira is focused on the discovery and development of therapies to treat chronic hepatitis B (CHB) infection. The company’s novel antiviral drug candidates have the potential to address

Sanofi will pay Hanmi €400m up front and possibly a further €3.5bn in development, registration and sales milestones, in addition to double digit royalties on net sales. In

Under the JAVELIN Lung 100 study, the companies aim to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who

Nucala is approved as an add-on maintenance treatment for patients aged 12 and older. It is administered once every four weeks by injection. The drug is a monoclonal